- Home
- SABR vs IRWD Comparison
SABR vs IRWD Comparison
Compare SABR & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SABR | IRWD |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 811.2M | 713.8M |
| IPO Year | 2014 | 2009 |
Fundamental Metrics
Financial Performance| Metric | SABR | IRWD |
|---|---|---|
| Price | $2.24 | $4.30 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.50 | ★ $7.67 |
| AVG Volume (30 Days) | ★ 4.3M | 1.5M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 283.56 | ★ 1400.00 |
| EPS | N/A | ★ 0.55 |
| Revenue | ★ $3,866,956,000.00 | $298,276,000.00 |
| Revenue This Year | $7.51 | $57.95 |
| Revenue Next Year | $3.46 | $4.39 |
| P/E Ratio | ★ N/A | $7.69 |
| Revenue Growth | 7.46 | ★ 8.88 |
| 52 Week Low | $0.81 | $1.26 |
| 52 Week High | $2.50 | $5.78 |
Technical Indicators
Market Signals| Indicator | SABR | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 54.96 | 55.15 |
| Support Level | $1.97 | $3.89 |
| Resistance Level | $2.27 | $4.52 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 48.04 | 73.15 |
Price Performance
Historical ComparisonAbout SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The marketplace segment represented 80% of total 2025 revenue and airline technology solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.